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1  | INTRODUC TION
“Haematological malignancies (HM) are type of cancers that originate 
in blood forming tissue such as bone marrow or in the cells of the im‐
mune system”.1 They are mainly of three types: leukaemia; lymphoma; 
and myeloma. Leukaemia types consist of acute lymphoid leukaemia 
(ALL), acute myeloid leukaemia (AML), chronic lymphoid leukaemia 
(CLL) and chronic myeloid leukaemia, whereas lymphomas are either 
Hodgkin or non‐Hodgkin (with indolent or aggressive non‐Hodgkin 
lymphomas). The UK has an incidence of 66.1 (annual rate per 100 000) 
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The wide range of health‐related quality‐of‐life (HRQoL) instruments used in haematol‐
ogy makes it challenging for haematologists and other care team members in practice to 
select, use and understand the scoring system and finally interpret the results. The main 
objectives of this study were to: (a) provide a comprehensive list of quality‐of‐life issues 
important to patients suffering from haematological malignancies, identified through the 
literature; (b) provide a list of health‐related quality‐of‐life (HRQoL) instruments used in 
haematological malignancies in both daily clinical practice and research; and (c) evaluate 
the relevance and comprehensibility of the identified instruments in haematological ma‐
lignancies. Systematic literature review of two databases, followed by addition of articles 
by manual searching, was carried out. The articles focusing on the primary studies, which 
have used semi‐structured/structured interviews or surveys to identify issues important 
to HM patients, and other studies describing the results of testing measurement proper‐
ties, such as reliability, validity and responsiveness of the instruments currently used to 
evaluate the HRQoL in different HMs, were included. Fifty‐seven studies reported devel‐
opment and validation of 30 HRQoL instruments, which have been used in haematology. 
Twenty‐four studies were identified using qualitative methods to report HRQoL issues 
and	symptoms	from	a	patient’s	perspective.	No	identified	instrument	captured	all	the	is‐
sues	identified	from	the	qualitative	studies.	None	of	the	instruments	reviewed	appeared	
to have been developed for use in clinical practice and specifically for patients with HM, 
except MyPOS. Furthermore, measurement properties were established, largely, in clini‐
cal trial scenarios. There is a need for development of a new HRQoL instrument entirely 
based on involvement of patients with haematological malignancies.
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as	per	HMRN	2004-14,2 with expected cases per year of 38730 for 
all haematological neoplasms and the reported median age at diagno‐
sis is 70.8 years.2 There have been advances in the treatment of hae‐
matological cancers, and it has led to improvement in survival, with 
an overall 5‐year relative survival of 69.2%.2 The improvement in sur‐
vival with HM has put emphasis on the long‐term effects of the dis‐
ease and its treatments. There is evidence that health‐related quality 
of life (HRQoL) of HM patients is greatly affected in both short term 
and long term.3‐8 Difficulty with physical and psychosocial activity, 
living with uncertainty, worrying about future and relapse and impact 
on work life are evident in survivors of HM and bone marrow trans‐
plant.3,9‐12 The high‐dose chemotherapy has a detrimental effect on 
many patients’ bone marrow which is usually followed by bone mar‐
row transplant (BMT),13,14 and this might have further complications 
such as graft‐versus‐host disease (GVHD).15‐17 Most of these studies 
which focus on identifying the quality‐of‐life (QoL) issues important to 
HM patients and evaluating their QoL have used the standard HRQoL 
instruments from the shelf for such purpose. There are a wide range 
of HRQoL instruments which are currently used in haematology to un‐
derstand such impact, some are general to oncology, and others are 
specific to a type of haematological disease. Furthermore, some of the 
instruments which are developed and used for patients with solid tu‐
mours (ST) are also used in haematology. However, the most important 
questions are as follows: Are the quality‐of‐life issues, the impact of the 
disease and treatment and patient needs the same for patients with 
ST and HM? There is evidence suggesting that this is not the case. In 
general, the psyche of patients with HMs is different to that of patients 
with ST, and consequently, the conceptual model for the two would be 
different based on the fundamental philosophical notion of “normative 
standard.” Thus, conceptually, patients make assessment/perception of 
their HRQoL with reference to their “normative standard” to which no 
one except patients themselves have access. For example, compared 
to solid tumours, patients with HMs: experience significant challenges 
with emotional/psychological disturbances18‐21; experience prolong 
periods of neutropenia22; have more frequent visit to intensive care 
unit or inpatients19; are more likely to die in the hospital, and use inten‐
sive care during the last days of their life23,24; receive less information 
on sexual side effects of the treatment as well as treatment informa‐
tion25; and are much less likely to be referred to the specialist palliative 
care later in the course of their illness.26‐28 Moreover, most of these 
instruments have been developed and validated for use in clinical trials, 
but the need of patient‐reported outcome (PRO) measures in clinical 
practice has been reported.29,30 The PROs intended for such purpose 
can be used to assist in clinical care and gather valuable information 
related to patient experiences. The wide range of HRQoL instruments 
makes it challenging for the clinical care team to select, use and under‐
stand the scoring system and finally interpret the results.
Several systematic reviews have been conducted in the past 
which only describes the HRQoL issues important to patients with 
different HMs,31‐33 but none except Osborne et al (2012) have 
assessed the content of the HRQoL instruments against these 
HRQoL issues. Furthermore, no systematic review has provided a 
comprehensive conceptual framework of the HRQoL themes and 
sub‐themes for patients with HMs. According to FDA, the adequacy 
of any HRQoL instrument depends on its characteristics including 
conceptual framework.34
The aim this systematic review was to identify the important 
HRQoL components to patients with HM required for developing 
a conceptual framework based on published literature to sup‐
port the need for development of a new instrument to assess the 
HRQoL of such patients in clinical practice as well as research. The 
main objectives of this systematic review were to: (a) provide a 
comprehensive list of quality‐of‐life issues important to patients 
suffering from haematological malignancies, identified through 
the literature; (b) provide a list of health‐related quality‐of‐life 
(HRQoL) instruments used in haematological malignancies in both 
daily clinical practice and research; and (c) evaluate the relevance 
and comprehensibility of the identified instruments in haemato‐
logical malignancies.
2  | METHODS
This systematic review focuses on the primary studies which have 
used semi‐structured/structured interviews or surveys to identify 
issues important to HM patients and other studies describing the 
results of psychometric testing of the instruments currently used to 
assess the HRQoL in different HMs.
2.1 | Search strategy
The literature search was carried out for both published and un‐
published studies. A 3‐step search strategy was used. For the first 
step,	search	was	carried	out	using	MEDLINE,	followed	by	additional	
search using SCOPUS with the same search string. In the third step, 
the reference list of all identified and included papers were scanned 
for any additional studies, followed by the manual search of the ar‐
ticles in the last step. The literature search was confined to only two 
databases due to limited access to other databases. All the studies in 
English languages, involving adult (18+ age) patients and published 
between 1 January 1990 and 31 December 2016 were considered 
for the inclusion in the review. The search terms were kept as in‐
clusive as possible to identify all the relevant studies. Since there 
are wide range of different haematological malignancies with wide 
range of published and ongoing research in haemato‐oncology, it 
might result in a number of irrelevant studies to the current research 
question. Hence, to narrow down the search period to a more rel‐
evant timeline and to process the most relevant identified studies, 
Osborne et al35 paper was used as a guide. The publication period of 
26 years considered for this systematic review is defined based on 
the reference list from Osborne et al.35
2.2 | Search terms
The search terms were finalised after discussion between the two 
reviewers (PG and YK) and were kept as inclusive as possible for the 
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identification of the studies (Figure 1). The term “clinical practice” 
refers to any consultation activity and provision of care that take 
place routinely in an outpatient setting.
2.3 | Study identification & screening
In the systematic review, all the experimental and epidemiological 
studies focusing on HM patients’ HRQoL were included irrespective 
of the study design. A novel approach used by Osborne et al35 in 
a review published for myeloma patients was used to screen every 
identified study for two different sets of inclusion and exclusion 
criteria. The two reviewers agreed on the two sets of the inclusion 
and the exclusion criteria (Figure 1). The “issues criteria” were de‐
signed to identify the studies which focus only on the areas which 
are reported important by the patients themselves rather than using 
any standardised instruments. Studies using only inductive meth‐
ods (qualitative) were included. The “instruments criteria” were 
designed to focus on the studies which describe the development 
and measurement properties of the instruments with respect to dif‐
ferent domains rather than focus on any single construct such as 
physical ability. Studies with a sample consisting >25% of patients 
with HM were included. This means studies with a mixed sample 
with different type of cancers (breast cancer, lung cancer, pancreatic 
cancer, etc.) were included only if more than 25% of the total sample 
were diagnosed with any haematological malignancy. The system‐
atic stepwise approach of inclusion and exclusion of the studies was 
adopted as per PRISMA guidelines.36
2.4 | Data collection and synthesis
The standardised data extraction tool from Cochrane collabora‐
tion was adopted for extracting the data. All the information was 
extracted by two reviewers (PG and YK) with consensus. Any unre‐
solved discrepancies were then discussed with the third reviewer, 
the adjudicator (SS), to reach consensus. A summary table of all the 
articles identified as per issues criteria was developed to summarise 
the HRQoL issues reported by the patients in such studies. The qual‐
ity assessment of all the articles included under “issue criteria” was 
carried out using a critical appraisal tool developed by Hawker et al37 
for qualitative studies. Hawker’s checklist was used to rate the nine 
components (abstract and title; introduction and aims; method and 
data; sampling; data analysis; ethics and bias; results; transferability 
or generalisability; and implications and usefulness: How important 
are these findings to policy and practice?) for each article as “good” 
(score 3), “fair” (2), “poor” (1), or “very poor” (0), with maximum pos‐
sible score of 27 for each article where higher score mean reflects 
better quality. The Hawker’s tool was chosen because it provides 
clear description of ratings, that is, “good,” “fair,” “poor” and “very 
poor,” and has been designed to assess quality of studies covering 
a variety of research paradigms. All the issues identified were then 
divided into two broad categories after reaching consensus between 
the two reviewers: “HRQoL issues” and “Signs and Symptoms” (in‐
cluding disease‐related symptoms and treatment side effects). The 
classification of the identified HRQoL issues in the literature into 
respective themes and sub‐themes was entirely based on the under‐
lying theoretical construct. The themes and sub‐themes generated 
were discussed among all three reviewers to reach consensus.
A second summary table of all the articles included in the instru‐
ments criteria was developed to summarise the QoL instruments and 
their measurement and psychometric properties for use in patients 
with HM.
3  | RESULTS
The two databases search resulted in 39 656 articles. All the identi‐
fied studies were screened by two reviewers (PG and YK) against 
two set of criteria. After a systematic inclusion and exclusion of 
articles,	24	articles	were	 included	as	per	the	 issues	criteria	and	57	
articles were included as per the instruments criteria. The PRISMA 
flow chart, presented in Figure 2, shows the different steps of iden‐
tification and screening of the selected articles and reasons of ex‐
clusion. Three articles reporting development and validation of on 
myelodysplastic syndrome (MDS), leukaemia and myeloma‐specific 
instrument	 (QoL-E,	 Fact-Leu	 and	 EORTC-MY24)	 were	 included	 in	
both sets.38-40
F I G U R E  1   Outline of methods and inclusion and exclusion 
criteria
282  |     GOSWAMI et Al.
3.1 | HRQoL issues reported important by patients
Twenty‐four articles were identified meeting the inclusion/exclu‐
sion criteria, using inductive method to identify HRQoL issues 
reported as important by patient with HMs. A total of six articles 
focused on leukaemia patients, ten on multiple myeloma (MM), six 
on patients with HMs undergone BMT, two on lymphoma and two 
MDS	patients.	A	total	of	14/24	articles	focused	on	exploring	 lived	
experience with disease, three on lived experience with SCT, two 
on response and psychological impact of intensive treatment, one 
on sexuality post‐SCT and three on development of disease‐specific 
instrument. A total of fifty different disease‐related symptoms and 
treatment side effects were identified from the selected articles and 
classified as “Signs and Symptoms” (Table 1). Overall, 21 HRQoL is‐
sues were reported important by the patients with different HMs 
(Table 1). The most highly reported disease‐ and treatment‐related 
symptoms across all included studies were as follows: tiredness; fa‐
tigue; feeling ill; nausea; and weakness. The most highly reported 
HRQoL life issues were as follows: impact on daily life; living with 
uncertainty; and financial impact.
Almost all the identified studies used purposive sampling for 
data collection without using sampling to redundancy approach, 
which is an important consideration in the qualitative research,41 
except three articles where inpatients were interviewed until satu‐
ration was achieved.39,42,43
3.2 | HRQoL instruments identified
Thirty different HRQoL instruments were identified from 57 in‐
cluded articles as per instruments criteria. Of these, four were 
F I G U R E  2   Prisma flow chart for the systematic review
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general measures used in oncology (EORTC‐QLQ‐C30, FACT‐G, 
FACT-AN	 and	 QAHL);	 twelve	 were	 disease-specific	 [three BMT 
specific (EORTC BMT module, FACT‐BMT and QoL‐BMT); four mul‐
tiple myeloma specific (EORTC‐QLQ‐MY24 & MY20, FACT‐MM and 
MyPOS); three leukaemia specific including one specific for chronic my‐
eloid leukaemia (EORTC Leu, FACT‐Leu and EORTC‐QLQ‐CML24); one 
specific to MDS (QoL‐E); and one specific for lymphoma (FACT‐Lym)]. 
Moreover, two were chemotherapy treatment specific (EORTC‐
QLQ‐HDC 19 & 29). Fact‐Fatigue was the only fatigue instrument 
identified used as HRQoL for patients with HMs. Eleven other 
instruments were generic QoL instruments used across different 
diseases	 (SF-36,	 SF-12,	 EQ-5D,	 15D,	 LIP,	 QLI,	 SUNS,	 SF-SUNS,	
SeiQoL‐DW, POMS, POMS‐SF). One full article eligible to be in‐
cluded as per the instruments criteria was inaccessible and hence 
excluded from the final list of included articles (LIP44). All the iden‐
tified instruments were developed and validated by collecting data 
from patients on different chemotherapy clinical trials or patients 
undergone/undergoing allogenic/autologous stem cell transplant, 
except MyPOS which has been developed and validated by col‐
lecting data from patients in palliative setting. MyPOS has been 
validated for use for myeloma patients45 and follicular lymphoma 
patients46 in clinical practice.




• Coping with disease 22 • Fatigue 16 • Lethargy during treatment 2
• Disease and Treatment 
related symptoms
21 •	 Nausea 9 •	 Neutropenia 2
• Performance ability 21 • Feeling ill 8 • Restlessness/agitation 2
• Psychological well‐being 
(emotional and cognitive)
18 • Infections 5 • Shortness of breath 2
• Burden of disease & 
treatment (long hospital 
stays, invasive diagnostic 
and treatment procedure)
15 • Swollen limb 5 • Weight loss 2
• Bleeding 4 • Bruising 1
• Living with uncertainty 14 • Bone aches 4 • Chest pain 1
• Physical well‐being 14 • Hair loss 4 • Chills 1
• Social well‐being/
participation
13 • Loss of appetite 4 • Clotting disorders 1
• Healthcare/healthcare 
professionals
11 • Tiredness 4 • Cough 1
• Support factors 11 • Weakness 4 • Disturbed taste 1
• Financial impact 10 • Anaemia 3 • Hip pain 1
• Impact on job/work life/
role change
10 • Cognitive impairment 3 • Heartburn 1
• Insecurity/body image 9 • Constipation 3 • Lymph node lumps/swelling 1
• Interpersonal relationships 9 • Fever 3 • Mouth sores 1
• Sexual problems/infertility 8 • Fractures 3 •	 Night	sweats 1
• Information about the 
disease and treatment
7 • General pain 3 •	 Numbness 1
• Insurance problems 4 • Insomnia 3 • Peripheral neuropathy 1
• Socio‐economic impact 4 • Back pain 2 • Renal failure 1
• Knowledge about the 
disease
3 • Bone lesion 2 • Shoulder pain 1
• Self‐esteem 3 • Brittle or broken bones 2 • Sore eyes 1
• Spiritual well‐being 3 • Diarrhoea 2 • Stomach area pain 1
• Drowsiness 2 • Thirst 1
• Dry mouth 2 • Tingling 1
n, number of studies reporting the issues/sign and symptoms.
aAll the studies identified and included in the systematic review to extract the HRQoL issues and signs and symptoms had used the same conceptual 
definition of health‐related quality of life. 
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3.3 | Content validity of HRQoL instruments
The ability of each instrument to capture the quality‐of‐life issues 
identified	from	the	24	qualitative	studies	is	shown	in	Table	2.	Seven	
EORTC modules were identified which are used for different haema‐
tological malignancies along with the core EORTC‐QLQ‐C30 ques‐
tionnaires. Similarly, six FACT modules were identified which are 
used together with the core FACT‐G questionnaire. Content of all 
the available questionnaires was checked for the identified HRQOL 
issues presented in Table 1. Subsequently, a number of HRQoL is‐
sues were identified from individual studies appraised for content 
validity of the employed HRQoL instruments (Table 3).
None	of	the	instrument	captured	all	the	22	identified	HRQoL	is‐
sues.	QoL-BMT	with	its	total	84	items	was	the	most	comprehensive	
instrument in covering the identified issues.
The important issues not captured by most of the thirty in‐
struments reviewed were as follows: burden of the disease and 
the treatment (9); issues related to healthcare and healthcare pro‐
fessionals (5); information about the disease and the treatment (5); 
feeling insecure and body image (10); issues related to insurance (2); 
socio‐economic impact (2); and spiritual well‐being (2).
All the generic instruments (SF‐36, SF‐12. EQ‐5D) were missing 
the important identified issues. Sei‐QoL‐DW is an open question‐
naire with no predefined items, and only five most important issues 
can be reported by a respondent. The POMS, POMS‐SF and LIP 
could not be obtained for content analysis, hence not being included 
in Table 2.
3.4 | Psychometric properties of the identified 
HRQoL instruments
A summary of the psychometric properties of the identified 
HRQoL	 instruments	 is	 presented	 in	 Table	4	 based	 on	 the	 crite‐
ria reported by Gruenewald et al47 and Osborne et al35 The table 
gives information about the sample used for development and 
validation of the instrument, validity (content, criterion, conver‐
gent and divergent), reliability (internal consistency, test‐retest), 
responsiveness, sensitivity to change and minimal clinically impor‐
tant difference (MCID).
Twenty‐three studies were identified extensively reporting the 
measurement/psychometric properties for the EORTC‐QLQ‐C30 
general oncology measure,4,48-70	 followed	 by	 EORTC-MY24	 mod‐
ule38,63,71‐73 and SF‐36 generic measure.74-79 Most of the studies 
provided evidences for internal consistency, convergent/divergent 
validity, floor/ceiling effect and responsiveness.
Content validity was reported for only five instruments, either 
represented as level of agreement between raters and items reported 
missing by the patients. All the studies reported internal consistency 
of >0.7 for different instruments, but none reported for SF‐12, EQ‐5D 
and 15‐D in the study population. The evidence for minimal clinically 
important difference and prognostic power of the instrument were 
identified for only eight instruments (EORTC‐QLQ‐C30, EORTC‐QLQ‐
MY24,	EORTC-QLQ-CML24,	FACT-AN,	FACT-Lym,	EQ-5D,	15D	and	
QLI;	Table	4).	Most	of	the	studies	had	patient	population	from	Europe	
(mainly Sweden, Germany and UK), followed by the USA.
The psychometric properties for EORTC‐QLQ were tested in 
wide range of patient population with different disease diagnosis, 
majority from MM, lymphoma and leukaemia. Only one study re‐
cruited patients with other neoplasm, and none reported recruiting 
patients with MDS. The psychometric properties of FACT‐G have 
been tested with 100% lymphoma patients in two studies and mixed 
sample of patients with different HMs in another two studies includ‐
ing	only	0.5%	MDS	and	no	patients	with	MPN.	The	SF-36,	SF-12,	
EQ‐5D, 15D, LIP, POMS and POMS‐SF also had focused on majority 
patients	with	myeloma,	followed	by	leukaemia,	and	lymphoma.	None	
of	the	identified	studies	had	patients	with	MDS	and	MPN.	Disease-
specific	 instruments	 EORTC	 (MY24,	MY20,	 HDC-19,	 HDC-29	 and	
CML-24),	FACT	(Leu,	AN,	BMT,	Lymph	and	MM),	QoL-E,	QoL,	BMT	
and MyPOS had recruited patients with respective type of haemato‐
logical malignancy. Hence, none of the instruments have undergone 
complete psychometric evaluation in patients with all types of hae‐
matological malignancies.
3.4.1 | Instruments for myeloma patients
EORTC-QLQ-C30	 and	 its	 myeloma	 modules	 (MY-24	 &	 revised	
MY‐20), followed by FACT‐G and its myeloma module (FACT‐MM), 
have been extensively validated with myeloma clinical trial patients. 
As reported by Osborne et al,35 the EORTC recommends MY20 
which has been revised after removing the social subscale from 
MY24,	which	is	an	important	issue	identified	from	the	24	qualitative	
studies included as per issues criteria in this review Table 1. Only 
one instrument, that is MyPOS, has been recently developed to be 
used in daily clinical practice. MyPOS total score is reported to be 
negatively correlated to the EORTC‐QLQ‐C30.45,46
3.4.2 | Instrument for lymphoma patients
FACT‐G and its lymphoma module FACT‐Lym have been identified 
for lymphoma patients. One study reporting the psychometric prop‐
erties of the FACT‐Lym was carried out only with non‐Hodgkin lym‐
phoma patients from USA. It is also noteworthy that no correlation 
was found between FACT subscales and social desirability scale.80 
Validation	of	FACT-G	was	carried	out	with	mixed	patient	groups.	No	
instrument has been validated to be used in daily clinical practice. 
Ceiling	effect	has	been	reported	for	4	items	from	FACT-G	scale	(nau‐
sea, feeling ill, forced to spend time in bed and losing hope in fight 
against illness).81
3.4.3 | Instruments for leukaemia patients
Out of 23 studies reporting psychometric properties of EORTC‐
QLQ‐C30, only five studies recruited patients with leukaemia 
(acute and chronic), the majority of these patients were diagnosed 
with AML. One study focused 100% on AML patients.69 Only one 
study has been identified reporting the psychometric properties 
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of	EORTC-QLQ-CML24.82	No	responsiveness,	 floor	and	ceiling	ef‐
fects have been reported. The validity results showed weak corre‐
lation between “satisfaction with care and information” and “social 
life” scales of QLQ‐C30.82 There was only one study identified for 
EORTC	Leu	scale,	which	was	included	as	part	of	the	EORTC	GIMENA	
AML8A and MRC AML10 clinical trial.83 Criterion validity, construct 
validity and MCID were not reported. For FACT‐Leu, there were two 
studies which enrolled the US and Japanese leukaemia patients. The 
one conducted with the US patients included all type of leukaemia.39
3.4.4 | Instruments for MDS patients
Apart from generic instruments used in haematology (EORTC‐QLQ‐
C30 and FACT‐G), only one reliable and valid instrument has been 
identified for MDS patients, that is QoL‐E. Most of the measurement 




DW, POMS and POMS‐SF have been used in haematology as ge‐
neric instruments. The highest evidence on measurement properties 
in haematological malignancy patients has been found for the SF‐36. 
One study reported correlation between the SF‐26 and FACT‐BMT 
scale.76 Two studies identified for the SF‐12 had patients only with 
MM; however, no detailed information for reliability and validity has 
been reported. Only one study reporting floor/ceiling effect, re‐
sponsiveness and MCID in MM patients was identified for the 15D 
instrument.	No	information	was	found	on	reliability	and	validity	of	
15D in patients with HMs. The QLI instrument had also one study 
reporting internal consistency and MCID. One study identified for 
LIP could not be included because of unavailability of the full paper.
4  | DISCUSSION
This	 systematic	 review	 has	 identified	 24	 studies	 using	 inductive	
method to identify HRQoL issues important to patients with differ‐
ent HMs and 30 HRQoL instruments with reported psychometric 
properties to varying robustness in 57 studies. The instrument which 
is most commonly used, with most extensive psychometric evalua‐
tion, is EORTC‐QLQ‐C30, although its validation across all types of 
haematological malignancies could not be established. The second 
most widely used instrument is FACT‐G for which the literature did 
not support validation across all types of haematological malignan‐
cies. The current literature for other disease‐specific instruments or 
disease‐specific modules of EORTC & FACT‐G does provide almost 
complete psychometric validation of the instrument in the respec‐
tive target patient population. The evidence for the generic instru‐
ments such as EQ‐5D and SF‐36, which are mostly used for health 
economic studies, does not provide complete information on psy‐
chometric properties of these instruments in patients with different 
HMs. The HRQoL issues identified through the literature as reported 
by patients should be considered as important QoL domain in under‐
standing the impact of HM and its treatments on patients’ daily life. 
Because there is no predefined sample size for qualitative research, 
it is of paramount importance to be able to capture all the issues 
important	to	these	patients.	Only	3	out	of	24	studies	reported	sam‐
pling to redundancy, which raises the question of saturation point 
and content validity of the instruments which have been developed 
using the information from such qualitative research.
The findings of this systematic review also supported previous 
findings that the quality‐of‐life issues, the impact of disease & treat‐
ment and patients’ needs are different for patients with HMs and 
STs,18‐30 and the identified instruments do not cover specific issues 
important to patients with HM, for example: worrying/uncertainty 
about future; eating and drinking habits; being burden to others; 
other people judging; travelling; going on holidays; difficulty leav‐
ing the house; appearance/body image; and sleeping patterns. It is a 
possibility that the results are also true for patients with other condi‐
tions; however, we cannot conclusively state this because it was not 
the objective of this SR and has not been studied. Whether or not 
this is true for other patients requires further systematic review for 
patients with other condition.
Further, our findings are in line with that of Osborne et al,35 that all 
studies, except one (ie study conducted with Japanese patients), have 
recruited patients from the USA and Europe for validation of the in‐
strument. Moreover, the vast majority of these validation studies were 
carried out with patients enrolled in clinical trials and all such instru‐
ments have been validated to be used in clinical trial, except MyPoS 
which has been specifically developed for use in daily clinical practice.
As reported by Greenhalgh (2009),84 PROs in clinical practice 
can be used as “screening instruments, monitoring instruments, as 
a method of promoting patient‐centred care, as a decision aid, as a 
communication facilitator, and means of monitoring the quality of 
patient care”. It is, therefore, of utmost importance that all the is‐
sues important to the patients are raised. The structure of SEIQoL‐
DW, which asks a patient to list the five most important issues do 
come close to fulfil the requirements on a PRO to be used in clinical 
practice, but limits the issues to five cues and also requires special 
training for the clinic staff, as reported by Osborne et al.35 Except 
SEIQoL‐DW and MyPOS, no other instrument provides a blank space 
for patients to enter any specific HRQoL issues important to them, 
which is not covered in the instrument. As PROs in clinical practice 
can be used on an individual level for facilitating the communication 
between the clinician and the patient, this information is of utmost 
importance.
One of the main barriers for use of a PRO in daily clinical prac‐
tice is the diversity of the PRO instruments. The 30 different PROs 
identified in this systematic review for use in patients with HMs can 
make it extremely difficult for the staff to implement them in daily 
clinical practice. This requires staff training and acquiring additional 
skills to implement different PROs for different HMs, assess, inter‐
pret the outcomes and utilise the information to inform patient con‐
sultation and to aid clinical decision‐making.
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The WHO defines the primary objective of cancer diagnosis and 
treatment as cure, prolongation of life and improvement of quality of 
life.85 Given the improved survival rate and living longer with a haema‐
tological malignancy, the use of PROs in daily clinical practice will cer‐
tainly enhance the chances of addressing the HRQoL issues for such 
patients in the real‐world situation. There is a lack of evidence in the 
literature for PROs validation in daily clinical practice. This systematic 
review has highlighted the complexity and the lack of appropriate PRO 
instrument for use in routine clinical practice despite the diversity of 
measures available. To address this, recently MyPOS has been devel‐
oped for myeloma patients. This has further highlighted the need for 
development of a new HRQoL instrument entirely based on involve‐
ment of patients with haematological malignancies, as both research 
partners and study participants. Furthermore, this new instrument 
could be a “generic” HRQoL instrument to be used for patients with 
different haematological malignancies, that is “one size fits all,” but this 
would warrant further discussion and debate involving all stakeholders.
4.1 | Recommendations for future research
The 30 HRQoL instrument identified in this systematic review and 
currently used in haematology are developed and validated with pa‐
tients in controlled clinical trials, except MyPOS. In order to better 
incorporate the patient‐reported outcome measures in daily clinical 
practice, the barrier of the lack of a standardised PRO instrument 
has to be overcome. The important HRQoL issues do differ for pa‐
tients with different haematological malignancies; however, most 
domains such as physical well‐being, social well‐being, emotional 
well‐being and functional well‐being are common. First, there is a 
need of an intensive qualitative research across all haematological 
malignancies to understand all the issues important to HM patients 
with “sampling to redundancy” as one of the important criteria to 
meet during such research. Second, there is a need to develop a new 
HRQoL instrument as a composite measure. This instrument would 
be able to measure both impact on HRQoL and capture the signs and 
symptoms that HM patients are experiencing.
4.2 | Limitations
The limitations of this review include the following: focus on adult 
patients diagnosed with HM; and literature published in English lan‐
guage. The search string was developed to be as inclusive as possi‐
ble. In addition, studies searched manually were also included; hence, 
the final list of included articles may vary slightly if carried out by a 
different researcher. Furthermore, the search did not include grey lit‐
erature for additional studies such as letter to editors or dissertations. 
However, PRISMA systematic review guidelines were strictly followed 
at each step and should be considered as strength of this review.
AUTHOR CONTRIBUTIONS
PG was the first reviewer, designed the protocol, defined the search 
terms, carried out the literature search, screened the literature based 
on inclusion and exclusion criteria, designed the extraction table and 
extracted the data, made the tables and figures, performed qual‐
ity scoring of the qualitative papers and wrote the first draft of the 
manuscript. YK was the second reviewer, defined the search terms, 
screened the literature on the basis of inclusion and exclusion cri‐
teria, carried out data extraction, performed quality scoring of the 
qualitative papers and reviewed the first draft of the manuscript. SS 
was the third reviewer, acted as the adjudicator to reach consensus, 
designed the protocol, supervised the work and reviewed the first 
draft of the manuscript.
CONFLIC T OF INTERE S T
The authors declare no competing financial interests.
ORCID
Pushpendra Goswami  https://orcid.org/0000-0002-3171-2495 
Sam Salek  http://orcid.org/0000-0002-4612-5699  
R E FE R E N C E S
	 1.	 NCI.	NCI	Dictionary	of	Cancer	Terms.	2016	[cited	May	1,	2016];	https://
www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45708.
 2. York., D.o.H.S.T.U.O. Haematological Malignancy Research 
Network	Incidence	&	Survival.	2017	[cited	Feb	25,	2017];	https://
www.hmrn.org/statistics/quick.
 3. Johnsen AT, Tholstrup D, Petersen MA, Pedersen L, Groenvold 
M. Health related quality of life in a nationally representative 
sample of haematological patients. Eur J Haematol. 2009;83(2): 
139-148.
	 4.	 Strasser-Weippl	K,	Ludwig	H.	Psychosocial	QOL	is	an	independent	
predictor of overall survival in newly diagnosed patients with mul‐
tiple myeloma. Eur J Haematol.	2008;81(5):374-379.
	 5.	 Holzner	 B,	 Kemmler	 G,	 Kopp	 M,	 Nguyen-Van-Tam	 D,	 Sperner-
Unterweger B, Greil R. Quality of life of patients with chronic lym‐
phocytic leukemia: results of a longitudinal investigation over 1 yr. 
Eur J Haematol.	2004;72(6):381-389.
	 6.	 Mols	F,	Aaronson	NK,	Vingerhoets	AJ,	et	al.	Quality	of	life	among	
long‐term non‐Hodgkin lymphoma survivors: a population‐based 
study. Cancer. 2007;109(8):1659‐1667.
 7. Persson L, Larsson G, Ohlsson O, Hallberg IR. Acute leukaemia or 
highly malignant lymphoma patients’ quality of life over two years: 
a pilot study. Eur J Cancer Care (Engl).	2001;10(1):36-47.
 8. Santos FR, Kozasa EH, Chauffaille MdeL, Colleoni GW, Leite JR. 
Psychosocial adaptation and quality of life among Brazilian pa‐
tients with different hematological malignancies. J Psychosom Res. 
2006;60(5):505‐511.
	 9.	 Brown	HN,	 Kelly	MJ.	 Stages	 of	 bone	marrow	 transplantation:	 a	
psychiatric perspective. Psychosom Med.	1976;38(6):439-446.
 10. Kornblith AB, Anderson J, Cella DF, et al. Hodgkin disease survi‐
vors at increased risk for problems in psychosocial adaptation. The 
cancer and leukemia group B. Cancer.	1992;70(8):2214-2224.
 11. Folsom TL, Popkin MK. Current and future perspectives on psychi‐
atric involvement in bone marrow transplantations. Psychiatr Med. 
1986;4(3):319-329.
 12. Sherman AC, Simonton S, Latif U, Spohn R, Tricot G. Psychosocial 
adjustment and quality of life among multiple myeloma patients 
undergoing evaluation for autologous stem cell transplantation. 
Bone Marrow Transplant.	2004;33:955.
     |  309GOSWAMI et Al.
	 13.	 Chao	NJ,	Amylon	MD,	Long	GD,	et	al.	Bone	marrow	transplanta‐
tion for hematologic malignancies: the Stanford experience. Clin 
Transpl. 1990;(1):157‐163.
	 14.	 Yee	GC,	McGuire	TR.	Allogeneic	bone	marrow	transplantation	in	the	
treatment of hematologic diseases. Clin Pharm.	1985;4(2):149-160.
 15. Deeg HJ, Antin JH. The clinical spectrum of acute graft‐versus‐
host disease. Semin Hematol.	2006;43(1):24-31.
 16. Bacigalupo A, Van Lint MT, Frassoni F, et al. Late complications 
of allogeneic bone marrow transplantation. Med Oncol Tumor 
Pharmacother.	1991;8(4):261-263.
 17. Sullivan KM, Mori M, Sanders J, et al. Late complications of al‐
logeneic and autologous marrow transplantation. Bone Marrow 
Transplant.	1992;10(Suppl	1):127-134.
 18. Gheihman G, Zimmermann C, Deckert A, et al. Depression and 
hopelessness in patients with acute leukemia: the psychological 
impact of an acute and life‐threatening disorder. Psychooncology. 
2016;25(8):979‐989.
 19. LeBlanc TW, Ritchie CS, Friedman F, et al. Adherence to measuring what 
matters items when caring for patients with hematologic malignancies 
versus solid tumors. J Pain Symptom Manage. 2016;52(6):775‐782.
	 20.	 Nissim	R,	Zimmermann	C,	Minden	M,	et	al.	Abducted	by	 the	 ill‐
ness: a qualitative study of traumatic stress in individuals with 
acute leukemia. Leuk Res.	2013;37(5):496-502.
 21. Shanafelt TD, Bowen D, Venkat C, et al. Quality of life in chronic 
lymphocytic	leukemia:	an	international	survey	of	1482	patients.	Br 
J Haematol.	2007;139(2):255-264.
 22. Rolston KVI. Infections in cancer patients with solid tumors: a re‐
view. Infect Dis Ther. 2017;6(1):69‐83.
	 23.	 Hui	D,	Didwaniya	N,	Vidal	M,	et	al.	Quality	of	end-of-life	care	in	
patients with hematologic malignancies: a retrospective cohort 
study. Cancer.	2014;120(10):1572-1578.
	 24.	 Howell	DA,	 Roman	E,	 Cox	H,	 et	 al.	Destined	 to	 die	 in	 hospital?	
Systematic review and meta‐analysis of place of death in haemato‐
logical malignancy. BMC Palliat Care. 2010;9:9.
 25. Padrnos L, Bennett R, Kosiorek HE, et al. Differences in cancer ed‐
ucation between patients with hematologic malignancies and solid 
tumor malignancies: lessons from a large multi‐disease patient ed‐
ucation symposium. Blood.	2016;128(22):4798.
	 26.	 Fadul	 N,	 Elsayem	 A,	 Palmer	 JL,	 Zhang	 T,	 Braiteh	 F,	 Bruera	
E. Predictors of access to palliative care services among pa‐
tients who died at a comprehensive cancer center. J Palliat Med. 
2007;10(5):1146-1152.
 27. Howell DA, Shellens R, Roman E, Garry AC, Patmore R, Howard MR. 
Haematological malignancy: are patients appropriately referred 
for specialist palliative and hospice care? A systematic review and 
meta‐analysis of published data. Palliat Med.	2011;25(6):630-641.
 28. Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care inter‐
vention on clinical outcomes in patients with advanced cancer: the proj‐
ect	ENABLE	II	randomized	controlled	trial.	JAMA.	2009;302(7):741-749.
 29. Dobrozsi S, Panepinto J. Patient‐reported outcomes in clinical prac‐
tice. Hematology Am Soc Hematol Educ Program. 2015;2015:501‐506.
 30. Higginson IJ, Carr AJ. Measuring quality of life: using quality of life 
measures in the clinical setting. BMJ. 2001;322(7297):1297‐1300.
 31. Allart‐Vorelli P, Porro B, Baguet F, Michel A, Cousson‐Gelie F. 
Haematological cancer and quality of life: a systematic literature 
review. Blood Cancer J. 2015;5:e305.
 32. Leak Bryant A, Lee Walton A, Shaw‐Kokot J, Mayer DK, Reeve BB. 
Patient‐reported symptoms and quality of life in adults with acute leu‐
kemia: a systematic review. Oncol Nurs Forum.	2015;42(2):E91-E101.
 33. Hjermstad MJ, Kaasa S. Quality of life in adult cancer patients 
treated with bone marrow transplantation–a review of the litera‐
ture. Eur J Cancer. 1995;31a(2):163‐173.
	 34.	 USFDA.	 Guidance	 for	 industry:	 patient-reported	 outcome	 mea‐
sures: use in medical product development to support labeling 
claims: draft guidance. Health Qual Life Outcomes.	2006;4:79.
 35. Osborne TR, Ramsenthaler C, Siegert RJ, Edmonds PM, Schey SA, 
Higginson IJ. What issues matter most to people with multiple my‐
eloma and how well are we measuring them? A systematic review 
of quality of life tools. Eur J Haematol.	2012;89(6):437-457.
 36. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting 
items for systematic reviews and meta‐analyses: the PRISMA 
statement. PLoS Med. 2009;6(7):e1000097.
 37. Hawker S, Payne S, Kerr C, Hardey M, Powell J. Appraising the 
evidence: reviewing disparate data systematically. Qual Health Res. 
2002;12(9):1284-1299.
 38. Stead ML, Brown JM, Velikova G, et al. Development of an EORTC 
questionnaire module to be used in health‐related quality‐of‐life 
assessment for patients with multiple myeloma. European organi‐
zation for research and treatment of cancer study group on quality 
of life. Br J Haematol.	1999;104(3):605-611.
 39. Cella D, Jensen SE, Webster K, et al. Measuring health‐related 
quality of life in leukemia: the Functional Assessment of Cancer 
Therapy‐Leukemia (FACT‐Leu) questionnaire. Value Health. 
2012;15(8):1051‐1058.
	 40.	 Oliva	Esther	N,	Borislav	NF,	Dimitrov	D.	Development	and	valida‐
tion of QOL‐E© instrument for the assessment of health‐related 
quality of life in myelodysplastic syndromes. Central Eur J Med. 
2013;8(6):835-844.
	 41.	 Streiner	 DL,	 Normal	 GR.	 Health Measurement Scales a Practical 
Guide to Their Development and Use, 3rd edn. Oxford, UK: Oxford 
University Press; 2003.
	 42.	 Potrata	B,	Cavet	J,	Blair	S,	Howe	T,	Molassiotis	A.	Understanding	
distress and distressing experiences in patients living with 
multiple myeloma: an exploratory study. Psychooncology. 
2011;20(2):127-134.
	 43.	 Bertero	C,	Eriksson	BE,	Ek	AC.	A	substantive	theory	of	quality	of	life	
of adults with chronic leukaemia. Int J Nurs Stud.	1997;34(1):9-16.
	 44.	 Stalfelt	 AM,	 Wadman	 B.	 Assessing	 quality	 of	 life	 in	 leuke‐
mia: presentation of an instrument for assessing quality of life 
in patients with blood malignancies. Qual Assur Health Care. 
1993;5(3):201‐211.
	 45.	 Osborne	TR,	Ramsenthaler	C,	Schey	SA,	Siegert	RJ,	Edmonds	PM,	
Higginson IJ. Improving the assessment of quality of life in the clin‐
ical care of myeloma patients: the development and validation of the 
Myeloma Patient Outcome Scale (MyPOS). BMC Cancer. 2015;15:280.
	 46.	 Davies	JM,	Osborne	TR,	Edmonds	PM,	et	al.	The	Myeloma	Patient	
Outcome Scale is the first quality of life tool developed for clin‐
ical use and validated in patients with follicular lymphoma. Eur J 
Haematol. 2017;98(5):508‐516.
	 47.	 Gruenewald	DA,	Higginson	 IJ,	 Vivat	 B,	 Edmonds	 P,	 Burman	RE.	
Quality of life measures for the palliative care of people severely 
affected by multiple sclerosis: a systematic review. Mult Scler. 
2004;10(6):690-704.
	 48.	 Bush	NE,	Haberman	M,	Donaldson	G,	Sullivan	KM.	Quality	of	life	
of 125 adults surviving 6‐18 years after bone marrow transplanta‐
tion. Soc Sci Med.	1995;40(4):479-490.
	 49.	 Kontodimopoulos	 N,	 Samartzis	 A,	 Papadopoulos	 AA,	 Niakas	 D.	
Reliability and validity of the Greek QLQ‐C30 and QLQ‐MY20 
for measuring quality of life in patients with multiple myeloma. Sci 
World J.	2012;2012:842867.
 50. Espinoza‐Zamora JR, Portilla‐Espinosa CM, Labardini‐Mendez 
JR,	 Cervera	 E,	Niesvisky	 R,	Onate-Ocana	 LF.	Quality	 of	 life	 in	
multiple myeloma: clinical validation of the Mexican‐Spanish 
version of the QLQ‐MY20 instrument. Ann Hematol.	2015;94(6): 
1017-1024.
	 51.	 Gulbrandsen	N,	Wisloff	F,	Brinch	L,	et	al.	Health-related	quality	of	life	
in multiple myeloma patients receiving high‐dose chemotherapy with 
autologous blood stem‐cell support. Med Oncol. 2001;18(1):65‐77.
 52. Andersson I, Ahlberg K, Stockelberg D, Persson LO. Patients’ per‐
ception of health‐related quality of life during the first year after 
310  |     GOSWAMI et Al.
autologous and allogeneic stem cell transplantation. Eur J Cancer 
Care (Engl). 2011;20(3):368‐379.
	 53.	 Frick	E,	Borasio	GD,	Zehentner	H,	Fischer	N,	Bumeder	I.	Individual	
quality of life of patients undergoing autologous peripheral blood 
stem cell transplantation. Psychooncology.	2004;13(2):116-124.
	 54.	 Frodin	U,	Borjeson	S,	Lyth	J,	Lotfi	K.	A	prospective	evaluation	of	
patients’ health‐related quality of life during auto‐SCT: a 3‐year 
follow‐up. Bone Marrow Transplant.	2011;46(10):1345-1352.
 55. Gimsing P, Carlson K, Turesson I, et al. Effect of pamidronate 30 mg 
versus 90 mg on physical function in patients with newly diagnosed 
multiple	myeloma	(Nordic	Myeloma	Study	Group):	a	double-blind,	
randomised controlled trial. Lancet Oncol. 2010;11(10):973‐982.
	 56.	 Gulbrandsen	N,	Hjermstad	MJ,	Wisloff	F.	Interpretation	of	quality	
of life scores in multiple myeloma by comparison with a reference 
population and assessment of the clinical importance of score dif‐
ferences. Eur J Haematol.	2004;72(3):172-180.
 57. Danaher EH, Ferrans C, Verlen E, et al. Fatigue and physical ac‐
tivity in patients undergoing hematopoietic stem cell transplant. 
Oncol Nurs Forum.	2006;33(3):614-624.
 58. Knols RH, de Bruin ED, Uebelhart D, et al. Effects of an outpatient 
physical exercise program on hematopoietic stem‐cell transplanta‐
tion recipients: a randomized clinical trial. Bone Marrow Transplant. 
2011;46(9):1245-1255.
 59. Kvam AK, Fayers P, Wisloff F. What changes in health‐related 
quality of life matter to multiple myeloma patients? A prospective 
study Eur J Haematol.	2010;84(4):345-353.
 60. Kvam AK, Fayers PM, Wisloff F. Responsiveness and minimal im‐
portant score differences in quality‐of‐life questionnaires: a com‐
parison of the EORTC QLQ‐C30 cancer‐specific questionnaire to 
the generic utility questionnaires EQ‐5D and 15D in patients with 
multiple myeloma. Eur J Haematol.	2011;87(4):330-337.
 61. Kvam AK, Wisloff F, Fayers PM. Minimal important differences and 
response shift in health‐related quality of life; a longitudinal study 
in patients with multiple myeloma. Health Qual Life Outcomes. 
2010;8:79.
 62. Ringdal K, Ringdal GI, Kaasa S, et al. Assessing the consistency of 
psychometric properties of the HRQoL scales within the EORTC 
QLQ‐C30 across populations by means of the Mokken Scaling 
Model. Qual Life Res.	1999;8(1–2):25-43.
 63. Uyl‐de Groot CA, Buijt I, Gloudemans IJ, et al. Health related qual‐
ity of life in patients with multiple myeloma undergoing a double 
transplantation. Eur J Haematol.	2005;74(2):136-143.
	 64.	 Viala	M,	Bhakar	AL,	de	la	Loge	C,	et	al.	Patient-reported	outcomes	
helped predict survival in multiple myeloma using partial least 
squares analysis. J Clin Epidemiol. 2007;60(7):670‐679.
 65. Wettergren L, Sprangers M, Bjorkholm M, Langius‐Eklof A. 
Quality of life before and one year following stem cell transplan‐
tation using an individualized and a standardized instrument. 
Psychooncology.	2008;17(4):338-346.




of life may be affected more by disease parameters and re‐
sponse to therapy than by haemoglobin changes. Eur J Haematol. 
2005;75(4):293-298.
 68. Wisloff F, Hjorth M. Health‐related quality of life assessed before 
and during chemotherapy predicts for survival in multiple myeloma. 
Nordic	Myeloma	Study	Group.	Br J Haematol. 1997;97(1):29‐37.
 69. Schumacher A, Wewers D, Heinecke A, et al. Fatigue as an import‐
ant aspect of quality of life in patients with acute myeloid leuke‐
mia. Leuk Res.	2002;26(4):355-362.
 70. Jones D, Vichaya EG, Wang XS, et al. Validation of the M. D. 
Anderson Symptom Inventory multiple myeloma module. J 
Hematol Oncol. 2013;6:13.
 71. Cocks K, Cohen D, Wisloff F, et al. An international field study of 
the reliability and validity of a disease‐specific questionnaire mod‐
ule (the QLQ‐MY20) in assessing the quality of life of patients with 
multiple myeloma. Eur J Cancer.	2007;43(11):1670-1678.
 72. Dubois D, Dhawan R, van de Velde H, et al. Descriptive and prog‐
nostic value of patient‐reported outcomes: the bortezomib expe‐
rience in relapsed and refractory multiple myeloma. J Clin Oncol. 
2006;24(6):976-982.
 73. Molassiotis A, Wilson B, Blair S, Howe T, Cavet J. Unmet supportive 
care needs, psychological well‐being and quality of life in patients 
living with multiple myeloma and their partners. Psychooncology. 
2011;20(1):88‐97.
	 74.	 Jansen	AJ,	Essink-Bot	ML,	Beckers	EA,	Hop	WC,	Schipperus	MR,	
Van Rhenen DJ. Quality of life measurement in patients with 
transfusion‐dependent myelodysplastic syndromes. Br J Haematol. 
2003;121(2):270-274.
	 75.	 Bird	L,	Arthur	A,	Niblock	T,	Stone	R,	Watson	L,	Cox	K.	Rehabilitation	
programme after stem cell transplantation: randomized controlled 
trial. J Adv Nurs. 2010;66(3):607‐615.
	 76.	 Imataki	O,	Nakajima	K,	Inoue	N,	Tamai	Y,	Kawakami	K.	Evaluation	
of QOL for stem cell transplantation recipients by SF‐36 and FACT‐
BMT: preliminary results of FACT‐BMT for Japanese patients. Gan 
To Kagaku Ryoho.	2010;37(5):847-851.
 77. Wilson RW, Jacobsen PB, Fields KK. Pilot study of a home‐based 
aerobic exercise program for sedentary cancer survivors treated 
with hematopoietic stem cell transplantation. Bone Marrow 
Transplant. 2005;35(7):721‐727.
 78. van Vliet M, van den Boogaard M, Donnelly JP, Evers AW, Blijlevens 
NM,	Pickkers	P.	Long-term	health	related	quality	of	life	following	
intensive care during treatment for haematological malignancies. 
PLoS ONE.	2014;9(1):e87779.
 79. Sutherland HJ, Fyles GM, Adams G, et al. Quality of life fol‐
lowing bone marrow transplantation: a comparison of pa‐
tient reports with population norms. Bone Marrow Transplant. 
1997;19(11):1129‐1136.
 80. Hlubocky FJ, Webster K, Cashy J, Beaumont J, Cella D. The devel‐
opment and validation of a measure of health‐related quality of life 
for non‐Hodgkin’s lymphoma: the Functional Assessment of Cancer 
Therapy—Lymphoma (FACT‐Lym). Lymphoma. 2013;2013:9.
 81. Yost KJ, Thompson CA, Eton DT, et al. The Functional Assessment 
of Cancer Therapy – General (FACT‐G) is valid for monitoring 
quality of life in non‐Hodgkin lymphoma patients. Leukemia & lym‐
phoma.	2013;54(2):290-297.
 82. Efficace F, Baccarani M, Breccia M, et al. International develop‐
ment of an EORTC questionnaire for assessing health‐related 
quality of life in chronic myeloid leukemia patients: the EORTC 
QLQ-CML24.	Qual Life Res.	2014;23(3):825-836.
 83. Watson M, Zittoun R, Hall E, Solbu G, Wheatley K. A modular 
questionnaire for the assessment of long‐term quality of life in 
leukaemia patients: the MRC/EORTC QLQ‐LEU. Qual Life Res. 
1996;5(1):15‐19.
	 84.	 Greenhalgh	J.	The	applications	of	PROs	in	clinical	practice:	what	
are they, do they work, and why? Qual Life Res. 2009;18(1):115‐123.
	 85.	 WHO.	 Cancer:	 Diagnosis	 and	 Treatment.	 2017	 [cited	 Feb	 25,	
2017]; http://www.who.int/cancer/treatment/en/.
 86. Schumacher A, Kessler T, Buchner T, Wewers D, van de Loo J. 
Quality of life in adult patients with acute myeloid leukemia receiv‐
ing intensive and prolonged chemotherapy – a longitudinal study. 
Leukemia.	1998;12(4):586-592.
 87. Bertero C, Eriksson BE, Ek AC. Explaining different profiles in 
quality of life experiences in acute and chronic leukemia. Cancer 
Nurs.	1997;20(2):100-104.
 88. Cooke L, Chung C, Grant M. Psychosocial care for adolescent and 
young adult hematopoietic cell transplant patients. J Psychosoc 
Oncol.	2011;29(4):394-414.
     |  311GOSWAMI et Al.
 89. Molassiotis A, Morris PJ. The meaning of quality of life and the 
effects of unrelated donor bone marrow transplants for chronic 
myeloid leukemia in adult long‐term survivors. Cancer Nurs. 
1998;21(3):205‐211.
 90. Richardson JL, Marks G, Levine A. The influence of symptoms of 
disease and side effects of treatment on compliance with cancer 
therapy. J Clin Oncol.	1988;6(11):1746-1752.
 91. Lee HG, Park EY, Kim HM, et al. Sexuality and quality of life after 
hematopoietic stem cell transplantation. Korean J Intern Med. 
2002;17(1):19‐23.
 92. Beeken RJ, Eiser C, Dalley C. Health‐related quality of life in hae‐
matopoietic stem cell transplant survivors: a qualitative study on 
the role of psychosocial variables and response shifts. Qual Life 
Res. 2011;20(2):153‐160.
	 93.	 Niederbacher	 S,	 Them	 C,	 Pinna	 A,	 Vittadello	 F,	 Mantovan	 F.	
Patients’ quality of life after allogeneic haematopoietic stem cell 
transplantation: mixed‐methods study. Eur J Cancer Care (Engl). 
2012;21(4):548-559.
	 94.	 Jones	WC,	Parry	C,	Devine	S,	Main	DS,	Okuyama	S.	Understanding	
distress in posttreatment adult leukemia and lymphoma survivors: 
a lifespan perspective. J Psychosoc Oncol.	2015;33(2):142-162.
 95. Thomas ML. The impact of myelodysplastic syndromes on 
quality of life: lessons learned from 70 voices. J Support Oncol. 
2012;10(1):37-44.
 96. Dahan JF, Auerbach CF. A qualitative study of the trauma and 
posttraumatic growth of multiple myeloma patients treated 
with peripheral blood stem cell transplant. Palliat Support Care. 
2006;4(4):365-387.
 97. Maher K, de Vries K. An exploration of the lived experiences of in‐
dividuals with relapsed multiple myeloma. Eur J Cancer Care (Engl). 
2011;20(2):267‐275.
 98. Vlossak D, Fitch MI. Multiple myeloma: the patient’s perspective. 
Can Oncol Nurs J.	2008;18(3):141-151.
 99. Wagner LI, Robinson D Jr, Weiss M, et al. Content development for 
the Functional Assessment of Cancer Therapy‐Multiple Myeloma 
(FACT‐MM): use of qualitative and quantitative methods for scale 
construction. J Pain Symptom Manage.	2012;43(6):1094-1104.
 100. Molassiotis A, Wilson B, Blair S, Howe T, Cavet J. Living with mul‐
tiple myeloma: experiences of patients and their informal caregiv‐
ers. Support Care Cancer. 2011;19(1):101‐111.
 101. Kelly M, Dowling M. Patients’ lived experience of myeloma. Nurs 
Stand.	2011;25(28):38-44.
 102. Osborne TR, Ramsenthaler C, de Wolf‐Linder S, et al. 
Understanding what matters most to people with multiple my‐
eloma: a qualitative study of views on quality of life. BMC Cancer. 
2014;14:496.
 103. Baz R, Lin HM, Hui AM, et al. Development of a conceptual 
model to illustrate the impact of multiple myeloma and its treat‐
ment on health‐related quality of life. Support Care Cancer. 
2015;23(9):2789‐2797.
	104.	 Grant	M,	Ferrell	B,	Schmidt	GM,	Fonbuena	P,	Niland	JC,	Forman	
SJ. Measurement of quality of life in bone marrow transplantation 
survivors. Qual Life Res.	1992;1(6):375-384.
 105. Tuchler H, Hofmann S, Bernhart M, et al. A short multilingual qual‐
ity of life questionnaire–practicability, reliability and interlingual 
homogeneity. Qual Life Res. 1992;1(2):107‐117.
 106. Andersson I, Hjermstad M, Stockelberg D, Persson LO. Health 
related quality of life in stem cell transplantation: clinical and 
psychometric validation of the questionnaire module, High Dose 
Chemotherapy (HDC‐19). Acta Oncol.	2008;47(2):275-285.
 107. Hall A, D’Este C, Tzelepis F, Sanson‐Fisher R, Lynagh M. The 
Survivor	Unmet	Needs	Survey	(SUNS)	for	haematological	cancer	
survivors: a cross‐sectional study assessing the relevance and psy‐
chometric properties. BMC Health Serv Res.	2014;14:211.
 108. McQuellon RP, Russell GB, Cella DF, et al. Quality of life mea‐
surement in bone marrow transplantation: development of 
the Functional Assessment of Cancer Therapy‐Bone Marrow 
Transplant (FACT‐BMT) scale. Bone Marrow Transplant. 
1997;19(4):357-368.
 109. Tefferi A, Hudgens S, Mesa R, et al. Use of the Functional 
Assessment of Cancer Therapy–anemia in persons with myelopro‐
liferative neoplasm‐associated myelofibrosis and anemia. Clin Ther. 
2014;36(4):560-566.
 110. Littlewood TJ, Kallich JD, San Miguel J, Hendricks L, Hedenus M. 
Efficacy of darbepoetin alfa in alleviating fatigue and the effect of 
fatigue on quality of life in anemic patients with lymphoprolifera‐
tive malignancies. J Pain Symptom Manage.	2006;31(4):317-325.
 111. Osterborg A, Brandberg Y, Molostova V, et al. Randomized, dou‐
ble‐blind, placebo‐controlled trial of recombinant human erythro‐
poietin, epoetin Beta, in hematologic malignancies. J Clin Oncol. 
2002;20(10):2486-2494.
 112. Sherman AC, Simonton S, Latif U, Plante TG, Anaissie EJ. Changes 
in quality‐of‐life and psychosocial adjustment among multiple 
myeloma patients treated with high‐dose melphalan and autol‐
ogous stem cell transplantation. Biol Blood Marrow Transplant. 
2009;15(1):12‐20.
 113. Díez‐Campelo M, Pérez‐Simón JA, González‐Porras JR, et al. 
Quality of life assessment in patients undergoing reduced inten‐
sity conditioning allogeneic as compared to autologous transplan‐
tation: results of a prospective study. Bone Marrow Transplant. 
2004;34:729.
	114.	 Knobel	H,	Loge	JH,	Brenne	E,	Fayers	P,	Hjermstad	MJ,	Kaasa	S.	
The validity of EORTC QLQ‐C30 fatigue scale in advanced cancer 
patients and cancer survivors. Palliat Med.	2003;17(8):664-672.
 115. Weiss M, Jacobus S, Wagner LI, et al. Development of the 
Functional Assessment of Cancer Therapy‐Multiple Myeloma 
(FACT‐MM) scale and validation in the Eastern Cooperative 
Oncology Group Trial E1A05. Blood.	2011;118(21):4184.
 116. Sherman AC, Simonton S, Latif U, Spohn R, Tricot G. Psychosocial 
adjustment and quality of life among multiple myeloma patients 
undergoing evaluation for autologous stem cell transplantation. 
Bone Marrow Transplant.	2004;33(9):955-962.
 117. Sherman AC, Coleman EA, Griffith K, et al. Use of a supportive 
care team for screening and preemptive intervention among mul‐
tiple myeloma patients receiving stem cell transplantation. Support 
Care Cancer.	2003;11(9):568-574.
	118.	 Oliva	EN,	Latagliata	R,	Lagana	C,	et	al.	Lenalidomide	in	International	
Prognostic Scoring System Low and Intermediate‐1 risk myel‐
odysplastic syndromes with del(5q): an Italian phase II trial of 
health‐related quality of life, safety and efficacy. Leuk Lymphoma. 
2013;54(11):2458-2465.
 119. Montgomery C, Pocock M, Titley K, Lloyd K. Individual quality 
of life in patients with leukaemia and lymphoma. Psychooncology. 
2002;11(3):239-243.
 120. Durner J, Reinecker H, Csef H. Individual quality of life in patients 
with multiple myeloma. SpringerPlus. 2013;2:397.
	121.	 Baker	F,	Denniston	M,	Zabora	J,	Polland	A,	Dudley	WN.	A	POMS	
short form for cancer patients: psychometric and structural evalu‐
ation. Psychooncology.	2002;11(4):273-281.
How to cite this article: Goswami P, Khatib Y, Salek S. 
Haematological malignancy: Are we measuring what is 
important to patients? A systematic review of quality‐of‐life 
instruments. Eur J Haematol. 2019;102:279‐311. https://doi.
org/10.1111/ejh.13203
